InTest Pre-Announces Record Q3 Orders and High-End Revenue

What happened

InTest Corporation pre-announced that Q3 2026 orders are expected to be a record and revenue will land at the high end of its guidance range for both Q3 and full year 2026. This announcement directly addresses the core concern from the prior quarter, where orders fell to $28.9 million and backlog declined 12.4% sequentially to $45.4 million, signaling that demand may be re-accelerating. The record orders likely reflect strengthening semiconductor demand, which the company had been struggling to convert into order-led growth, as the industry test equipment recovery gains traction. However, the pre-announcement does not yet provide details on gross margin or ending backlog, which were the other two critical metrics under scrutiny after Q2's margin drop to 40.5% and backlog depletion. Investors will look to the full Q3 report in early November to confirm whether the order strength translated into margin recovery toward the 44% guidance and a rebuild of backlog above $50 million.

Implication

For investors, the pre-announcement reduces the key risk that order replenishment was failing, but it does not yet confirm the quality of those orders or the sustainability of demand. If the final Q3 results show gross margin rebounding to around 44% and backlog rising above $50 million, the bull case becomes more credible and the stock could re-rate toward the $16.50 trim level. However, if the record orders were driven by one or two large projects or came with lower pricing, the margin improvement may be muted and the backlog rebuild may be temporary. The stock currently trades around $13.59, which still leaves meaningful upside to the $17 bull scenario but also downside to the $11 bear scenario if execution falters. A prudent approach is to wait for the full Q3 report, and consider adding on any weakness if the margin and backlog numbers validate the order strength.

Thesis delta

The prior WAIT thesis was based on insufficient order replenishment and weak margin execution, but this pre-announcement directly addresses the order concern with record Q3 bookings. This shifts the risk-reward from neutral to potentially positive, though the thesis is not yet upgraded to BUY because margin recovery and backlog rebuild remain unconfirmed. If the full Q3 results confirm those metrics, we would upgrade to BUY with a near-term fair value of $16.50.